BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19120370)

  • 1. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?
    Wardrop D; Steensma DP
    Br J Haematol; 2009 Mar; 144(6):809-17. PubMed ID: 19120370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
    Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
    Patnaik MM; Tefferi A
    Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
    Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
    Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Classification and diagnosis of essential thrombocythemia].
    Kirito K
    Rinsho Byori; 2012 Jun; 60(6):553-9. PubMed ID: 22880233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
    Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
    Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Refractory anaemia with ringed sideroblasts (RARS) associated with marked thrombocytosis: a provisional entity in the WHO classification of haematological malignancies].
    Gérard J; Dubois-Galopin F; Gardembas-Pain M; Defaux JB; Schmidt-Tanguy A; Godon A; Geneviève F; Blanchet O; Ifrah N; Zandecki M
    Ann Biol Clin (Paris); 2005; 63(6):653-9. PubMed ID: 16330386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: case report and literature review.
    Găman M; Vlădăreanu AM; Onisai M
    Rom J Morphol Embryol; 2012; 53(3):645-50. PubMed ID: 22990561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.
    Gurevich I; Luthra R; Konoplev SN; Yin CC; Medeiros LJ; Lin P
    Am J Clin Pathol; 2011 Mar; 135(3):398-403. PubMed ID: 21350094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
    Raya JM; Arenillas L; Domingo A; Bellosillo B; Gutiérrez G; Luño E; Piñán MA; Barbón M; Pérez-Sirvent ML; Muruzábal MJ; Yánez L; García L; Lemes A; Navarro JT; Elosegi A; Cortés MA; Villegas A; Durán MA; Ardanaz M; Florensa L;
    Int J Hematol; 2008 Nov; 88(4):387-395. PubMed ID: 18820995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
    Ziarkiewicz M; Dwilewicz-Trojaczek J; Pastwińska A; Chmarzyńska E; Paszkowska-Kowalewska M; Koperski Ł; Jędrzejczak WW; Ziarkiewicz-Wróblewska B
    Pol J Pathol; 2010; 61(2):105-9. PubMed ID: 20924996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.
    Jekarl DW; Han SB; Kim M; Lim J; Oh EJ; Kim Y; Kim HJ; Min WS; Han K
    Korean J Hematol; 2010 Mar; 45(1):46-50. PubMed ID: 21120162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
    Steensma DP; Caudill JS; Pardanani A; McClure RF; Lasho TL; Tefferi A
    Haematologica; 2006 Dec; 91(12 Suppl):ECR57. PubMed ID: 17194663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Malcovati L; Della Porta MG; Pietra D; Boveri E; Pellagatti A; Gallì A; Travaglino E; Brisci A; Rumi E; Passamonti F; Invernizzi R; Cremonesi L; Boultwood J; Wainscoat JS; Hellström-Lindberg E; Cazzola M
    Blood; 2009 Oct; 114(17):3538-45. PubMed ID: 19692701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
    Broseus J; Florensa L; Zipperer E; Schnittger S; Malcovati L; Richebourg S; Lippert E; Cermak J; Evans J; Mounier M; Raya JM; Bailly F; Gattermann N; Haferlach T; Garand R; Allou K; Besses C; Germing U; Haferlach C; Travaglino E; Luno E; Pinan MA; Arenillas L; Rozman M; Perez Sirvent ML; Favre B; Guy J; Alonso E; Ahwij N; Jerez A; Hermouet S; Maynadié M; Cazzola M; Girodon F
    Haematologica; 2012 Jul; 97(7):1036-41. PubMed ID: 22532522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis.
    Lee MY; Jang S; Park CJ; Cho YU
    Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
    Hall J; Foucar K
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.